John Quisel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

John quiselGayle rossGuowen liuNaseema gangatAmy dickeyChristina tartagliaDisc medicine incEuropean hematology associationVerge scientific communicationsExchange commissionMadrid spainChief executive officerDisc medicineTopline resultsPlacebo controlled trialOpen label trial

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJohn quiselChristina tartagliaVerge scientific communicationsExchange commissionDisc medicine incDevelopment expensesAmerican society of hematology annual meetingChief executive officerBusiness highlightsUpcoming milestonesHeme synthesis modulatorPatient global impressionPediatric disease designationAnti hemojuvelin antibodyHepcidin suppression

Sun blind: Disc Medicine s phase II data throw shade on bitopertin

Sun blind: Disc Medicine s phase II data throw shade on bitopertin
bioworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bioworld.com Daily Mail and Mail on Sunday newspapers.

John quiselDisc medicine incDisc medicine

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light.

Christina tartagliaJohn quiselDisc medicine incVerge scientific communicationsExchange commissionPatient global impressionChief executiveErythropoietic protoporphyriaX linked protoporphyriaPrivate securities litigation reform actAnnual report

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

Matt brown unsplashJohn quiselDrug administrationDisc medicine incPatient global impressionDisc medicine